Qualigen Therapeutics Files 8-K Report
Ticker: AIXC · Form: 8-K · Filed: Jan 28, 2025 · CIK: 1460702
Sentiment: neutral
Topics: 8-K, financial-statements, regulatory-disclosure
TL;DR
Qualigen Therapeutics filed an 8-K on Jan 28, 2025, covering financial statements and Reg FD disclosures.
AI Summary
On January 28, 2025, Qualigen Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and includes a Regulation FD Disclosure. The company is incorporated in Delaware and its principal executive offices are located in Carlsbad, California.
Why It Matters
This 8-K filing provides an update on Qualigen Therapeutics' regulatory disclosures and financial exhibits, which can be important for investors to understand the company's current reporting status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K report detailing financial statements and exhibits, with no immediate indication of significant new risks or material events.
Key Numbers
- 001-37428 — SEC File Number (Identifies the company's filing with the SEC.)
- 26-3474527 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- January 28, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Carlsbad, California (location) — Address of principal executive offices
- RITTER PHARMACEUTICALS INC (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report financial statements and exhibits, along with a Regulation FD Disclosure.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on January 28, 2025.
In which state is Qualigen Therapeutics, Inc. incorporated?
Qualigen Therapeutics, Inc. is incorporated in Delaware.
What is the address of Qualigen Therapeutics, Inc.'s principal executive offices?
The principal executive offices of Qualigen Therapeutics, Inc. are located at 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
What was the former name of Qualigen Therapeutics, Inc.?
The former name of Qualigen Therapeutics, Inc. was RITTER PHARMACEUTICALS INC.
Filing Stats: 556 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-01-28 16:10:33
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share QLGN The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 20KB
- 0001493152-25-003982.txt ( ) — 252KB
- qlgn-20250128.xsd (EX-101.SCH) — 3KB
- qlgn-20250128_lab.xml (EX-101.LAB) — 33KB
- qlgn-20250128_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: January 28, 2025 By: /s/ Kevin Richardson II Kevin Richardson II, Interim Chief Executive Officer